글로벌 키메라 항원 수용체 T(CAR-T) 세포 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 규모

최근 몇 년 동안, 키메라 항원 수용체(car) t-세포 치료 부문은 예외적인 성장을 이루었으며, 앞으로도 계속될 것으로 예상됩니다. 연구 개발 활동에 대한 투자 증가, 신규 업체 진입, 제품 혁신, 기술적 돌파구, 효과적인 자원 배분, 지역 및 고객 기반을 확대하기 위한 사업 경쟁사 간의 경쟁 심화가 산업 성장에 기여합니다.

Data Bridge Market Research는 2021년에 1,965.8백만 달러였던 키메라 항원 수용체 T(CAR-T) 세포 시장이 2029년까지 287억 1,400만 달러로 급증할 것으로 분석하고, 2022년부터 2029년까지의 예측 기간 동안 39.82%의 CAGR을 보일 것으로 예상합니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자, 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석, 규제 프레임워크가 포함되어 있습니다.

보고 범위 및 시장 세분화                               

시장 정의

CAR-T therapy is a type of treatment in which a patient's T cells, which are immune cells, are genetically engineered in the lab to kill cancer cells. T cells are collected from a patient's blood. T cells in the lab are given the gene for a specific receptor that binds to a specific protein on the patient's cancer cells. Chimeric antigen receptors are a special kind of receptor (CAR). CAR-T cells are mass-produced in the lab and then injected into the patient. CAR-T therapy is used to treat certain types of blood cancers and is also being studied for use in other cancers.

Chimeric Antigen Receptor T (CAR-T) Cells Market Dynamics

Drivers

• Increasing occurrences of cancer

In the forecast period of 2022-2029, rising levels of investment for the development of advanced and technical solutions and products, an increase in the number of cell therapy clinical studies, and the growth of the pharmaceutical industry will all help to accelerate the growth of the chimeric antigen receptor T (CAR-T) cells market. In the forecast period, increasing use of cells for the treatment of various hematologic and solid tumour types would enhance numerous prospects, resulting in the expansion of the chimeric antigen receptor T (CAR-T) cells market.

• Increasing number of patients

The rise in the frequency of cancer, the increase in the number of patients who have failed to respond to alternative treatments, and the rise in healthcare costs are all predicted to promote the growth of the chimeric antigen receptor (CAR)-T cell therapy market in the forecast period.

• Increasing approvals for Car-T cell therapy products

As people become more aware of this novel way of treating cancer, demand for auto T cell therapy products rises. As a result, leading market players are working on new products, which is driving the industry forward. The US Food and Drug Administration authorized Yescarta, a cell-based gene therapy, in October 2017 to treat adult patients with certain kinds of large B-cell lymphoma. Yescarta's clearance is a breakthrough in the field of CAR-T cell treatments for cancer patients.

• Increasing R&D therapies

By 2028, the global CAR T-cell treatment industry is estimated to reach $15 billion. CAR T-cell therapy providers are likely to benefit from increased attention on research and development medicines for cancers such as lung cancer, colorectal cancer, multiple myeloma cancer, and prostate cancer. In addition to cancer, researchers are verifying the function of therapy in a variety of other diseases, such as HIV, autoimmune disorders, infections, and others, which will drive the market's growth throughout the forecast period.

Opportunities

In addition, as people become more aware of efficiency, the market for chimeric antigen receptor (CAR)-T cell treatment is expected to develop in the coming years. However, the potential for cytokine release syndrome (CRS) and other neurological disorders as a result of cell therapy could provide further growth prospects for the chimeric antigen receptor (CAR)-T cell therapy industry in the near future.

Restraints/Challenges

In the predictable future, high treatment costs and negative effects associated with CAR T cell use would operate as a market restraint for the expansion of chimeric antigen receptor T (CAR-T) cells.

This chimeric antigen receptor T (CAR-T) cells market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the chimeric antigen receptor T (CAR-T) cells market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Covid-19 impact on Chimeric Antigen Receptor T (CAR-T) Cells Market

The COVID-19 epidemic has caused widespread economic and social disruption. The disease has infiltrated various sectors' value and supply chains, including the market for chimeric antigen receptor (car) t-cell treatment. The authorities implemented lockdowns in several regions. We'll look at both demand and supply to see how the COVID-19 epidemic has affected the global market. To provide a summary, the short- and long-term effects of the COVID-19 pandemic would be investigated. During and after the outbreak, this would aid in the development of business plans for all market participants, including manufacturers, vendors, suppliers, distributors, and end-users.

Recent Development

• In February 2021, After getting FDA permission for commercialization in the United States, Bristol Myers Squibb marketed Breyanzi (lisocabtagene maraleucel). Breyanzi is a cell-based gene therapy used to treat certain kinds of big B-cell lymphoma in adults.
• In July 2020, After getting FDA permission for commercialization in the United States, Kite Pharma, a Gilead Sciences subsidiary, introduced Tecartus. Tecartus (brexucabtagene autoleucel, formerly KTE-X19) is the first and only CAR T-cell therapy licenced for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

Global Chimeric Antigen Receptor T (CAR-T) Cells Market Scope

The chimeric antigen receptor T (CAR-T) cells market is segmented on the basis of target antigen, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Target Antigen

• CD19
• CD22
• Others

Application

• Acute Lymphoblastic Leukaemia
• Diffuse Large B-Cell Lymphoma
• Others

End User

• Hospitals
• Cancer Research Centres
• Clinics

Chimeric Antigen Receptor T (CAR-T) Cells Market Regional Analysis/Insights

The chimeric antigen receptor T (CAR-T) cells market is analysed and market size insights and trends are provided by country, target antigen, application and end-user as referenced above.

The countries covered in the chimeric antigen receptor T (CAR-T) cells market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominating the chimeric antigen receptor T (CAR-T) cells market due to the high prevalence of cancer.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the prevalence of better healthcare infrastructure along with growing disposable income of the people.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Chimeric Antigen Receptor T (CAR-T) Cells Market Share Analysis

키메라 항원 수용체 T(CAR-T) 세포 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 있습니다. 위에 제공된 데이터 포인트는 키메라 항원 수용체 T(CAR-T) 세포 시장과 관련된 회사의 초점에만 관련이 있습니다.

키메라 항원 수용체 T(CAR-T) 세포 시장에서 활동하는 주요 업체는 다음과 같습니다.

• 노바티스 AG(스위스)
• 파이저 주식회사(미국)
• 길리드 사이언스 주식회사(미국)
• Autolus Therapeutics(영국)
• CARsgen Therapeutics Co. Ltd. (영국)
• 주노 테라퓨틱스(Juno Therapeutics, Inc.)(미국)
• 소렌토 테라퓨틱스 주식회사(미국)
• 레전드 바이오텍(미국)
• Calyxt Inc. (프랑스)
• 머스탱 바이오(미국)
• 블루버드 바이오 주식회사(미국)
• 셀진 코퍼레이션(미국)
• 유레카 테라퓨틱스 주식회사(미국)
• Avacta Life Sciences Ltd. (영국)

SKU-52938